GSK (GSK) president acquires notional ADS in executive supplemental savings plan

Rhea-AI Filing Summary

GSK plc reported an executive share-related transaction involving President Maya Martinez-Davis. She acquired 6.679 notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account at a price of $51.9900 per ADS. The transaction took place on 23 March 2026 on the New York Stock Exchange.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$51.9900	6.679
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-03-23
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: March 25, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transaction did GSK (GSK) report in this Form 6-K?

GSK reported that President Maya Martinez-Davis acquired 6.679 notional American Depositary Shares. The acquisition occurred within her GSK Executive Supplemental Savings Plan account, reflecting routine compensation-related share accumulation rather than an open-market purchase program.

What type of security did the GSK (GSK) executive acquire?

The executive acquired notional American Depositary Shares (ADS) of GSK. These ADS are referenced within an executive supplemental savings plan, rather than as directly traded ordinary shares, and are linked to GSK’s US-listed ADS with ISIN US37733W2044.

At what price and volume were GSK (GSK) ADS acquired by the executive?

Maya Martinez-Davis acquired 6.679 notional GSK ADS at a price of $51.9900 per ADS. This was recorded as a single transaction within her executive supplemental savings plan, rather than a series of separate trades in the market.

When and where did the reported GSK (GSK) transaction take place?

The transaction took place on 23 March 2026 on the New York Stock Exchange. GSK’s filing identifies the trading venue as XNYS and records the event as a single acquisition of notional ADS for the executive’s supplemental savings plan.

Who is the GSK (GSK) executive involved in this Form 6-K transaction?

The executive is Maya Martinez-Davis, identified as President at GSK. The filing classifies her as a person discharging managerial responsibilities, and the transaction relates to her holdings within the GSK Executive Supplemental Savings Plan account.